Company news

Organon & Co. news in 2025

Organon & Co.'s news releases, calls and decks from 2025, newest first.

View company

TetraScience and Organon Collaborate to Modernize Quality Control Data Management

December 16, 2025

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

November 17, 2025

Organon Reports Results for the Third Quarter Ended September 30, 2025

November 10, 2025

New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities

November 8, 2025

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

November 7, 2025

Laborie Announces Agreement to Acquire the JADA® System from Organon

November 7, 2025

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

November 6, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

October 27, 2025

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

September 19, 2025

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

September 2, 2025

Organon Reports Results for the Second Quarter Ended June 30, 2025

August 5, 2025

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

July 22, 2025

Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

July 7, 2025

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

July 2, 2025

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

May 27, 2025

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

April 15, 2025

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

April 15, 2025

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

April 1, 2025

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

March 28, 2025

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

March 8, 2025

Calls in 2025

Decks in 2025